600 patients66,869 observations120 daysLIVE

Patient P-01831

Synthetic patientNBL-101 · Day 115 · 75+ · F · baseline S15Open companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
75%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S15
  2. Day 46 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 49 SC-12 recommendedSupportive Compound SC-12
  4. Day 50 Patient acceptedStarted SC-12 in the companion
  5. Day 56 GI symptom burden −23% vs expectedSupportive Compound SC-12
  6. Day 62 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days
  • Inflammatory activity-10
  • GI instability-8
  • Nutritional resilience+7
  • Toxicity-6
  • Treatment adherence+3

What helped?

  • Supportive Compound SC-12Day 49
    Result: symptom burden −23%
LIFE OS recommendation
GI Support Protocol GI-04
80%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 84% showed improvement
  • median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 35/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 57
  • Autonomic recovery 65
    • WearableResting HR 74 bpm
    • Wearable1,462 steps/day
    • WearableShort sleep window
  • Drug metabolism and exposure 55
    • DNADPYD *2A → slower clearance
    • BloodToxicity index 52
  • Mucosal barrier integrity 30
    • Daily logGI symptom score 50 and rising
    • WearableSleep 5.6 h, below personal baseline
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • DPYD *2A heterozygous
    Slower drug clearance
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 35/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
52 ms
Sleep
5.7 h
Steps
1,983
Resting HR
77 bpm
Daily log: GI score 50, nutritional resilience 43, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0158159%S18GI-04improved51
P-0138951%S14SC-12improved46
P-0141349%S14GI-04improved44
P-0154449%S15GI-04improved50
P-0171649%S14GI-04improved56
P-0130748%S14GI-04improved43
P-0136548%S14SC-12improved49
P-0143648%S14GI-04improved38
P-0170748%S14GI-04improved57
P-0184248%S14NP-02improved55
P-0147347%S14GI-04improved51
P-0148647%S18GI-04improved47